Article
Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.
Clinical lung cancer - 1 Sept 2023
Yonesaka Kimio, Hayashi Hidetoshi, Nakamura Atsushi, Sato Yuki, Azuma Koichi, Sakata Shinya, Tachihara Motoko, Ikeda Satoshi, Yokoyama Toshihide, Ito Kentaro, Yano Yukihiro, Matsumoto Hirotaka, Daga Haruko, Hata Akito, Sakai Kazuko, Chiba Yasutaka, Nishio Kazuto, Yamamoto Nobuyuki, Nakagawa Kazuhiko
Abstract excerpt
BACKGROUND: Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has limited treatment options for patients with EGFR-mutated non-small-cell lung cancer (NSCLC). Although osimertinib or afatinib alone induced drug-resistant clones with EGFR secondary mutation in a preclinical model, its combination prevented the appearance of these mutations. We investigated alternating-dose...
Topics
Join the communities discussing this publication.